Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 23rd, 2026

LECO_Weekly-Healthcare-News_3-23-2026Download
  1. GE HealthCare (NASD: GEHC) Completes $2.3B Acquisition of Intelerad to Bolster Cloud-First Imaging Solutions GE HealthCare (NASDAQ: GEHC) has finalized its acquisition of Intelerad Medical Systems, a leading provider of enterprise imaging software. This strategic move is designed to accelerate GE HealthCare’s transition toward cloud-based enterprise solutions and “precision care.” By integrating Intelerad’s informatics platform, GE HealthCare aims to improve clinician workflows and data accessibility across hospital systems. The acquisition enhances the company’s digital health portfolio, focusing on scalable, interoperable imaging tools that reduce administrative burdens. This deal reflects the broader industry trend of medical technology giants acquiring software firms to dominate the healthcare data infrastructure market. (Link)
  2. Movano (NASD: MOVE) Completes All-Stock Merger with Corvex (NASD: CVEX) and Rebrands Movano Health (NASDAQ: MOVE) and Corvex have completed a strategic merger, creating a unified entity focused on AI-driven cloud infrastructure for healthcare. Movano, known for its wearable medical technology and the Evie Ring, will leverage Corvex’s cloud capabilities to enhance its data analytics and patient monitoring services. The merger aims to create a “cloud infrastructure powerhouse” capable of processing large-scale health data for clinical and consumer applications. This transaction reflects the merging of hardware and software capabilities in the wearable tech space to provide more comprehensive, actionable health insights through artificial intelligence. (Link)
  3. Knowtion Health Acquires Revly to Enhance RCM and AI-Driven Denial Management Management via its financial sponsors Arsenal Capital Partners, Sunstone Partners and Ardan Equity Knowtion Health, a leader in revenue cycle management (RCM) and claim denial resolution, has acquired Revly, an AI-powered billing technology company. Knowtion Health is a portfolio company of Sunstone Partners. This acquisition integrates Revly’s advanced automation into Knowtion’s existing platforms to help hospitals and health systems recover unpaid claims more efficiently. By combining human expertise with Revly’s AI, Knowtion aims to reduce the rising rate of insurance denials. This deal underscores the high demand for AI-driven solutions in the administrative healthcare space to combat labor shortages and complex payer requirements. (Link)
  4. Prestige Consumer Healthcare (NYSE: PBH) to Acquire Breathe Right from Foundation Consumer Healthcare Prestige Consumer Healthcare Inc. (NYSE: PBH) has signed a definitive agreement to acquire the Breathe Right nasal strip brand from Foundation Consumer Healthcare. This acquisition strengthens Prestige’s portfolio of leading over-the-counter consumer brands, specifically within the respiratory care segment. Breathe Right is the global leader in the nasal strip category, and this move is expected to be immediately accretive to Prestige’s earnings and free cash flow. The deal highlights Prestige’s ongoing strategy of acquiring established, high-growth consumer health brands to leverage its existing retail distribution network and marketing infrastructure. (Link)
  5. Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC (NASD: IAC) An affiliate of Pacific Avenue Capital Partners has completed the acquisition of Care.com from IAC (NASDAQ: IAC). Care.com is the world’s leading platform for finding and managing high-quality family care, including childcare, senior care, and specialized medical care. Under the new ownership of Pacific Avenue, the company plans to invest in product innovation and expand its enterprise offerings for employers. This private equity buyout signifies a shift for Care.com as it moves away from a conglomerate structure to focus on independent growth in the rapidly expanding digital caregiving marketplace. (Link)
  6. Aria Care Partners Acquires Coronado Dental to Expand On-Site Clinical Services in Arizona via its financial sponsor Serent Capital Aria Care Partners, a leading provider of onsite ancillary medical services for skilled nursing facilities, has acquired Coronado Dental. This acquisition marks Aria’s entry into the Arizona market. Aria Care Partners, which is backed by private equity investment, focuses on delivering dental, vision, hearing, and podiatry services directly to residents in long-term care facilities. By acquiring Coronado Dental, Aria expands its footprint and reinforces its position as a dominant player in the specialized geriatric clinical services sector. The deal highlights the consolidation of fragmented ancillary care providers under larger, PE-backed management platforms. (Link)
  7. Blackstone-Backed (NYSE: BX) Chartis Acquires Health Tech Firm Leap AI The Chartis Group, a healthcare advisory and analytics firm backed by Blackstone (NYSE: BX), has acquired Leap AI. Leap AI specializes in healthcare-specific artificial intelligence automation, focusing on streamlining clinical and administrative workflows. This acquisition allows Chartis to integrate advanced AI capabilities into its consulting services, helping hospital systems improve operational efficiency. For Blackstone, this move represents a continued investment in “applied AI” within the healthcare sector, moving beyond general software into tools that solve specific provider pain points. The deal highlights the aggressive expansion of tech-enabled consulting platforms. (Link)
  8. WELL Health (TSX: WELL) Subsidiary WELLSTAR Acquires Two Billing Platforms to Expand National Footprint WELLSTAR, a subsidiary of WELL Health Technologies Corp. (TSX: WELL), has completed the acquisition of two strategic billing and back-office service providers. These acquisitions expand WELL’s national billing platform, which now serves medical professionals across six Canadian provinces. WELL Health continues its “buy-and-build” strategy, acquiring fragmented healthcare IT and billing services to create a unified, tech-enabled provider network. By scaling its billing division, WELL increases its recurring revenue and strengthens its position as the largest owner-operator of outpatient clinics in Canada, providing essential administrative infrastructure to thousands of physicians. (Link)
  9. James River Home Health Acquires Golden Rule Hospice to Expand End-of-Life Care Services James River Home Health and Hospice has completed the acquisition of Golden Rule Hospice. This strategic move expands James River’s service area and strengthens its specialized hospice care offerings. The acquisition is part of James River’s effort to build a comprehensive home-based care network that covers both skilled home health and end-of-life services. As the demand for aging-in-place solutions grows, regional providers like James River are increasingly acquiring boutique hospice agencies to achieve better economies of scale and improve clinical outcomes through standardized care models. (Link)
  10. Loma Linda University Health and Kara Health Form Joint Venture for New Hospice Agency Loma Linda University Health (LLUH) has partnered with Kara Health to launch a joint venture called Loma Linda University Hospice. Kara Health is a tech-enabled home care and hospice provider. This partnership combines LLUH’s clinical excellence with Kara Health’s proprietary technology platform to provide high-quality, data-driven end-of-life care. The joint venture aims to improve patient transitions from the hospital to the home and enhance the palliative care experience through remote monitoring and streamlined communication. This model illustrates the growing trend of health systems partnering with startups to modernize home health. (Link)
  11. Palladium Equity Partners Acquires Majority Stake in DME Express from Waypoint Capital Palladium Equity Partners, LLC has announced its acquisition of a majority interest in DME Express, a leading provider of medical equipment services to the hospice industry. The stake was acquired from Waypoint Capital Partners. DME Express specializes in high-touch delivery and management of durable medical equipment (DME), primarily serving hospice and post-acute care facilities. Palladium’s investment is aimed at accelerating the company’s geographic expansion and enhancing its service capabilities. This transaction underscores the increasing interest from private equity in specialized logistics and equipment providers within the value-based care and end-of-life care sectors. (Link)
  12. SportsMed Physical Therapy Expands to 54 Clinics with New Connecticut Locations SportsMed Physical Therapy, a leading provider of physical therapy, chiropractic, and acupuncture services, has opened two new clinics in Connecticut. These openings bring the company’s total to 54 locations across New Jersey and Connecticut. SportsMed, which has received investment from private equity firms, continues to pursue a rapid “de novo” growth strategy alongside strategic acquisitions. The company focuses on a multidisciplinary approach to musculoskeletal health. This expansion reflects the high investor interest in the physical therapy sector due to its predictable revenue streams and the increasing demand for non-invasive pain management solutions. (Link)
  13. Allina Health to join Sutter Health in $26B proposed transaction in Strategic Realignment Allina Health has released a strategic announcement regarding its long-term operational and investment plan for its Minnesota-based health system. The plan includes a focus on clinical service realignment and infrastructure investment to support high-growth areas like cardiovascular and oncology care. While not a sale of the company, the announcement details strategic capital allocations aimed at improving financial stability and patient access. This news is critical for investors monitoring the financial health of non-profit systems and their shift toward outpatient-focused care models in a challenging economic environment for hospitals. (Link)
  14. Providence Explores Strategic Options Including Sale of Providence Health Plan Providence, one of the largest non-profit health systems in the U.S., has announced it is exploring strategic options for the sale of its Providence Health Plan (PHP) division. PHP is a regional health insurer serving hundreds of thousands of members in Oregon and Washington. This potential divestiture is part of Providence’s effort to shore up its balance sheet and focus resources on its core hospital operations. A sale would likely attract interest from major national insurers or private equity groups seeking a foothold in the Pacific Northwest insurance market. (Link)
  15. Valir Health Expands Senior Care Presence in Oklahoma City Valir Health has announced the acquisition of a prominent senior care facility in Oklahoma City, continuing its expansion in the post-acute care and geriatric services sector. Valir Health provides a range of services including inpatient rehabilitation, hospice care, and billing solutions. This acquisition is part of Valir’s broader strategy to consolidate senior living and rehabilitation services within the Oklahoma region. By integrating this new facility, Valir aims to improve care coordination for the elderly population. The deal reflects a regional trend of mid-sized healthcare companies expanding their physical footprint to meet growing geriatric demand. (Link)

Venture Deals

  1. Unnatural Products Raises $45 Million Series B Led by Nextech Invest and Frazier Life Sciences with participation from Northpond Ventures, Cool Springs Financial, and others to Advance Peptide Therapeutics Unnatural Products (UNP), a biotech firm specializing in macrocyclic peptide therapeutics, has secured $45 million in Series B financing. The round was led by Nextech Invest and Frazier Life Sciences, with participation from Northpond Ventures, Cool Springs Financial, and others. The company uses a platform that combines AI and medicinal chemistry to create “unnatural” macrocycles that can hit difficult-to-target intracellular proteins. The capital will be used to advance its lead oncology programs into the clinic and expand its platform capabilities. This funding highlights continued investor confidence in AI-driven drug discovery platforms targeting previously “undruggable” pathways. (Link)
  2. Conduit Health Raises $17 Million Series A Led by Drive Capital to Expand AI-Powered DME Access Conduit Health has raised $17 million in Series A funding led by Drive Capital. Conduit Health operates an AI-powered platform designed to streamline access to Durable Medical Equipment (DME). The platform connects healthcare providers, payers, and suppliers to automate the ordering and fulfillment process, which is traditionally fragmented and manual. The investment will be used to scale the company’s technology and expand its market presence. This deal underscores the venture capital interest in solving administrative bottlenecks within the home health and medical supply chain using modern software-as-a-service (SaaS) models. (Link)
  3. Verily Secures $300 Million Investment Led by Alphabet (NASDAQ: GOOGL) to Advance Precision Health AI Verily, the life sciences subsidiary of Alphabet (NASDAQ: GOOGL), has secured a $300 million investment to accelerate its precision health AI strategy. This funding round, supported by parent company Alphabet and other institutional investors, will focus on scaling Verily’s data-driven clinical research and care management solutions. The company aims to use the capital to further integrate artificial intelligence into its “Lightship” clinical trial platform and its chronic condition management tools. This massive investment signals Google’s long-term commitment to becoming a dominant player in the convergence of big data, AI, and clinical healthcare. (Link)
  4. Turquoise Health Raises $40 Million Series B Led by Adams Street Partners with participation from Andreessen Horowitz (a16z) and BoxGroup to Power Healthcare Price Transparency Turquoise Health, a healthcare pricing platform, has raised $40 million in Series B funding led by Adams Street Partners, with participation from Andreessen Horowitz (a16z) and BoxGroup. Turquoise Health provides software that enables hospitals and payers to comply with price transparency regulations and manage data-driven contracts. The company intends to use the funds to expand its “ClearContract” platform, which automates the negotiation and management of payer-provider contracts. This investment highlights the growing importance of data transparency tools as healthcare shifts toward value-based care and more complex reimbursement models. (Link)
  5. Condor Software Raises $24 Million Series A Led by Bessemer Venture Partners with participation from Casdin Capital and existing investors for Clinical Trial Finance Management Condor Software has secured $24 million in Series A funding led by Bessemer Venture Partners, with participation from Casdin Capital and existing investors. Condor Software provides a specialized financial management platform for biotech companies to track and manage the complex costs associated with clinical trials. The company aims to replace manual spreadsheets with automated workflows that integrate with clinical and financial data. The new capital will be used to scale its engineering team and accelerate product development, reflecting the niche but high-value demand for fintech solutions tailored specifically to the life sciences industry. (Link)
  6. RAAPID Secures Series A Extension Led by Celesta Capital to Scale Neuro-Symbolic AI for Medical Coding RAAPID has secured a Series A extension funding round led by Celesta Capital to scale its “Neuro-Symbolic” AI-powered medical coding and risk adjustment platform. The company’s technology helps healthcare providers and insurers automate the complex process of clinical documentation and coding, ensuring accurate reimbursement. By combining deep learning with symbolic AI, RAAPID aims to provide higher accuracy and transparency than traditional LLM models. The funding will support geographic expansion and further R&D. This deal illustrates the shift toward specialized, high-accuracy AI tools for administrative healthcare tasks where error margins are critical. (Link)
  7. Health Universe Raises $6 Million Seed Round Led by Eniac Ventures for AI Agents in Medical Workflows Health Universe, a platform for developing and deploying AI “agents” for medical workflows, has raised $6 million in a seed funding round led by Eniac Ventures. The platform allows developers and clinicians to collaborate on AI models that automate specific clinical tasks, such as surgery scheduling or pathology reporting. Health Universe provides the infrastructure for hosting and running these models securely in a compliant environment. This investment highlights the emerging “AI-as-a-Service” model within healthcare, where platforms provide the tools for specialized, agentic AI to be integrated into daily hospital operations. (Link)
Spenser Lin No Comments

Lawrence, Evans, and Co. (LECO) Presenting Sponsor for HCMIS 2026 (May 26-28th, 2026)

HCMIS-2026-LECO-Presenting-Sponsor-AnnouncementDownload

Lawrence, Evans & Co. LLC (LECO) is a leading national boutique healthcare financial advisory and investment banking firm headquartered in Columbus, OH.

Founded in 2003, LECO delivers specialized lead advisory services to lower middle-market private companies across the healthcare ecosystem. The firm’s experienced senior professionals provide a full suite of solutions, including:

● Sell-side and buy-side mergers & acquisitions advisory
● Capital raising (debt and equity)
● Valuation and Consulting
● Financial and Operational restructuring

LECO serves a wide range of healthcare sectors and related businesses, such as hospitals, senior housing, home health & hospice, behavioral and mental health, physician groups, longevity, revenue cycle management (RCM), digital health, HCIT, CCM, RPM, RTM, cyber & managed IT, pharma services, supply chain, life sciences, space health, real estate & more.

With a strong track record in driving strategic transactions, maximizing value, and fostering innovation, LECO is a trusted partner for healthcare providers, service companies, technology firms, and investors seeking impactful deals.

For more details on services, current engagements, or to connect, visit www.lawrenceevans.com. 

Contact Neil Johnson, Managing Partner, or David Opalek, Director

info@lawrenceevans.com or 614-448-1304

The 6th annual Healthcare Capital Markets & Innovation Summit HCMIS May 26-28th 2026 Columbus OH brings together 400+ dealmakers, investors, and innovators in healthcare.

More Information at www.healthcarecapitalmarkets.com

This conference is where leading healthcare industry executives gather and speak on the latest investment and partnership topics. In addition to hearing from top healthcare innovators, attendees will also have access to:

● Dealmaking & networking with industry leaders, executives, PE, VC, family offices, bankers, accountants, lawyers, and other professionals
● In-person one-on-one meetings with fellow event participants that can be locked in with a dedicated meeting scheduler
● Company presentations from executives seeking capital, partnerships, or to sell.
● ACG Columbus in collaboration with an event Day 2
● Healthcare Venture Studios (top leaders and investors in the space)
● Participants from over 32 US States and Globally
● Over $500 million of deal investment activities as a result of introductions
● Read Pitchbook’s Key Takeaways from HCMIS 2025
● *NEW*: PreConference Workshops Tues afternoon
● *NEW*: Emerging Company/Start Up Section – special pricing for qualified companies

Watch HCMIS 2026 Video

Watch HCMIS 2025 Highlights

HCMIS Overview Summary

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)